CBT
AGIO icon

Capital Bank & Trust’s Agios Pharmaceuticals AGIO Stock Holding History

Capital Bank & Trust’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,504
Closed -$89K – 304
2020
Q1 		$89K Sell
2,504
-19,731
-89% -$912K ﹤0.01% 354
2019
Q4 		$1.06M Sell
22,235
-223,724
-91% -$8.46M 0.01% 191
2019
Q3 		$7.97M Sell
245,959
-4,765
-2% -$197K 0.11% 115
2019
Q2 		$12.5M Buy
250,724
+530
+0.2% +$28.3K 0.15% 108
2019
Q1 		$16.9M Buy
250,194
+144,592
+137% +$8.42M 0.21% 96
2018
Q4 		$4.87M Sell
105,602
-132,653
-56% -$8.19M 0.07% 136
2018
Q3 		$18.4M Sell
238,255
-2,920
-1% -$235K 0.23% 95
2018
Q2 		$20.3M Buy
241,175
+3,967
+2% +$346K 0.27% 95
2018
Q1 		$19.4M Buy
237,208
+128,148
+118% +$9.9M 0.26% 96
2017
Q4 		$6.24M Sell
109,060
-12,135
-10% -$764K 0.09% 134
2017
Q3 		$8.09M Sell
121,195
-1,410
-1% -$84.7K 0.1% 130
2017
Q2 		$6.31M Buy
+122,605
New +$6.27M 0.08% 139

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Capital Bank & Trust's AGIO Position: Q2 2020 in Review

Capital Bank & Trust sold out of Agios Pharmaceuticals (AGIO) in Q2 2020, closing a stake of 2,504 shares — an estimated $89K sold.

Capital Bank & Trust first reported a position in AGIO in Q2 2017 and held it in 12 quarters. The position peaked at $20.3M in Q2 2018. 217 funds tracked by Wall St. Rank hold AGIO as of Q2 2020.

  • Capital Bank & Trust reported no remaining Agios Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Capital Bank & Trust sold 2,504 Agios Pharmaceuticals shares in Q2 2020, an estimated $89K.
  • Capital Bank & Trust first reported a position in Agios Pharmaceuticals in Q2 2017 and held it in 12 quarters.
  • Capital Bank & Trust's Agios Pharmaceuticals position peaked at $20.3M in Q2 2018.
  • 217 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.